- Nesti L, Pugliese NR, Sciuto P, et al. Mechanisms of reduced peak oxygen consumption in subjects with uncomplicated type 2 diabetes. Cardiovasc Diabetol. 2021;20(1):124.
- Nesti L, Pugliese NR, Sciuto P, Natali A. Type 2 diabetes and reduced exercise tolerance: a review of the literature through an integrated physiology approach. Cardiovasc Diabetol. 2020;19(1):134.
- Natali A, Nesti L, Fabiani I, Calogero E, Di Bello V. Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. Cardiovasc Diabetol. 2017;16(1):130.
Empagliflozin shown to benefit patients with normal LVEF values but reduced GLS values
Key messages
- Empagliflozin has a neutral impact on aerobic fitness and left ventricle (LV) systo-diastolic functions, both at rest and during exercise, however, it can exert an early and sustained amelioration of myocardial contractility in those with subclinical dysfunction.
- SGLT2 inhibitors, such as empagliflozin, can directly affect myocardial contractility in selected patients with subclinical LV systolic dysfunction, possibly justifying their benefit in HF primary prevention.
